期刊
EXPERT REVIEW OF GASTROENTEROLOGY & HEPATOLOGY
卷 11, 期 12, 页码 1119-1134出版社
TAYLOR & FRANCIS LTD
DOI: 10.1080/17474124.2017.1373017
关键词
Biomarker; gastrointestinal disease; faecal calprotectin; lactoferrin; phagocyte derived protein; faecal occult blood testing; mucins; fatty acid binding proteins; microbiome; volatilome
资金
- Engineering and Physical Sciences Research Council (EPSRC) [EP/K034537/1]
- entitled Sonopill
- Engineering and Physical Sciences Research Council [EP/K034537/1] Funding Source: researchfish
- EPSRC [EP/K034537/1] Funding Source: UKRI
Introduction: A biomarker is a measurable indicator of normal biologic processes, pathogenic processes or pharmacological responses. The identification of a useful biomarker is challenging, with several hurdles to overcome before clinical adoption. This review gives a general overview of a range of biomarkers associated with inflammatory bowel disease or colorectal cancer along the gastrointestinal tract.Areas covered: These markers include those that are already clinically accepted, such as inflammatory markers such as faecal calprotectin, S100A12 (Calgranulin C), Fatty Acid Binding Proteins (FABP), malignancy markers such as Faecal Occult Blood, Mucins, Stool DNA, Faecal microRNA (miRNA), other markers such as Faecal Elastase, Faecal alpha-1-antitrypsin, Alpha2-macroglobulin and possible future markers such as microbiota, volatile organic compounds and pH.Expert commentary: There are currently a few biomarkers that have been sufficiently validated for routine clinical use at present such as FC. However, many of these biomarkers continue to be limited in sensitivity and specificity for various GI diseases. Emerging biomarkers have the potential to improve diagnosis and monitoring but further study is required to determine efficacy and validate clinical utility.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据